Your browser doesn't support javascript.
SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic non-hospitalised individuals in New Zealand: a multicentre cross sectional observational study.
Fox-Lewis, Andrew; Fox-Lewis, Shivani; Beaumont, Jenna; Drinkovic, Dragana; Harrower, Jay; Howe, Kevin; Jackson, Catherine; Rahnama, Fahimeh; Shilton, Blair; Qiao, Helen; Smith, Kevin K; Morpeth, Susan C; Taylor, Susan; Blakiston, Matthew; Roberts, Sally; McAuliffe, Gary.
  • Fox-Lewis A; Microbiology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
  • Fox-Lewis S; Virology-Immunology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand. Electronic address: afoxlewis@gmail.com.
  • Beaumont J; Microbiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
  • Drinkovic D; Microbiology Department, North Shore Hospital, Waitemata District Health Board, Auckland, New Zealand.
  • Harrower J; Auckland Regional Public Health Service, Auckland District Health Board, Auckland, New Zealand.
  • Howe K; Auckland Regional Public Health Service, Auckland District Health Board, Auckland, New Zealand.
  • Jackson C; Nga Tai Ora Public Health Northland, Northland District Health Board, Whangarei, New Zealand.
  • Rahnama F; Virology-Immunology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
  • Shilton B; Labtests, Auckland, New Zealand.
  • Qiao H; Microbiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
  • Smith KK; Microbiology Department, North Shore Hospital, Waitemata District Health Board, Auckland, New Zealand.
  • Morpeth SC; Microbiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
  • Taylor S; Microbiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
  • Blakiston M; Microbiology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand; Labtests, Auckland, New Zealand.
  • Roberts S; Microbiology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
  • McAuliffe G; Virology-Immunology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand; Labtests, Auckland, New Zealand.
Pathology ; 53(4): 530-535, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1142192
ABSTRACT
We conducted a multicentre cross sectional observational study of laboratory, public health and hospitalisation data for PCR-confirmed COVID-19 cases within the New Zealand Northern Region, between 12 February and 8 June 2020. The aim of this study was to describe population level SARS-CoV-2 upper respiratory tract (URT) viral load dynamics by stratifying positivity rates and polymerase chain reaction (PCR) cycle threshold (Ct) values of URT samples from COVID-19 cases by days since symptom onset, and to explore utility of Ct values in determining length of time post-infection and thus potential infectivity. Of 123,124 samples tested for SARS-CoV-2 by PCR, 579 samples (407 positive and 172 negative) from 368 symptomatic non-hospitalised individuals with PCR-confirmed infection were included. Sample positivity rate was 61.5% (8/13) for pre-symptomatic samples, rising to 93.2% (317/340) for samples collected during the purported symptomatic infectious period (days 0-10 post-symptom onset), and dropping to 36.3% (82/226) for post-infectious period samples (day 11 onwards). URT viral load peaked shortly after symptom onset, with median Ct values ranging 20.00-29.99 until 15 days post-symptom onset, and >30.00 after this time. Of samples with a Ct value of <20.00, 96.1% were collected during the symptomatic infectious period. However, of samples with a Ct value ≥30.00 and ≥35.00, 46.9% and 18.5%, respectively, were also collected during the symptomatic infectious period. The findings of this study indicate that at or soon after symptom onset represents the optimum time to test for SARS-CoV-2 in the URT, with median Ct values suggesting the useful testing window extends until around 15 days post-symptom onset. In asymptomatic individuals or those with unknown dates of symptom onset, Ct values <20.00 imply recent onset/potential infectivity, but Ct values ≥30.00 or ≥35.00 do not exclude recent onset/potential infectivity. Individual sample Ct values should not be used as an absolute marker of length of time post-infection or to exclude infectivity where date of symptom onset is unavailable.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Load / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Oceania Language: English Journal: Pathology Year: 2021 Document Type: Article Affiliation country: J.pathol.2021.01.007

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Load / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Oceania Language: English Journal: Pathology Year: 2021 Document Type: Article Affiliation country: J.pathol.2021.01.007